Print
Email
Sciclone Pharmaceuticals Inc. has a market cap of $247.87 million; its shares were traded at around $4.25 with a P/E ratio of 9.88 and P/S ratio of 2.91.
This is the annual revenues and earnings per share of SCLN over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of SCLN.
CEO Recent Trades:
- President & CEO Friedhelm Blobel bought 2,000 shares of SCLN stock on 08/16/2011 at the average price of 5.11. Friedhelm Blobel owns at least 35,000 shares after this. The price of the stock has decreased by 16.83% since.
CFO Recent Trades:
- Senior VP Finance & CFO Gary Titus bought 1,075 shares of SCLN stock on 08/18/2011 at the average price of 4.65. Gary Titus owns at least 26,766 shares after this. The price of the stock has decreased by 8.6% since.
- Senior VP Finance & CFO Gary Titus bought 2,197 shares of SCLN stock on 06/15/2011 at the average price of 4.96. Gary Titus owns at least 25,691 shares after this. The price of the stock has decreased by 14.31% since.
This is the insider trade history vs. stock price of SCLN. For the complete insider trading history of SCLN, click here.
Directors and Officers Recent Trades:
- Director Roberto Camerini sold 68,334 shares of SCLN stock on 06/14/2011 at the average price of 4.97. The price of the stock has decreased by 14.49% since.
For the complete insider trading history of SCLN, click here.
Subscribe RSS
